Generic Name and Formulations:
Cangrelor 50mg/vial; lyophilized pwd for IV inj after reconstitution and dilution; contains mannitol, sorbitol.
The Medicines Company
Indications for KENGREAL:
As adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
Initially 30mcg/kg IV bolus prior to PCI, followed immediately by 4mcg/kg/min IV infusion; continue infusion for ≥2hrs or for duration of PCI, whichever is longer. Transitioning to oral P2Y12 therapy: see full labeling.
Significant active bleeding.
Increased risk of bleeding. Pregnancy (Cat.C). Nursing mothers.
P2Y12 platelet inhibitor (ATP analog).
Do not administer clopidogrel or prasugrel during infusion.
Bleeding, renal impairment, dyspnea, hypersensitivity reactions.
Single-use vial (10mL)—1, 10
Neurology Advisor Articles
- Optimizing Treatment for Patients With Chronic Sciatica: Gabapentin vs Pregabalin
- Tiglutik Now Available for the Treatment of Amyotrophic Lateral Sclerosis
- Modifiable CV Risk Factors Within Healthy Range Indicative of CV Morphology, White Matter Lesions
- A New Look at Demyelination and White Matter Density in Multiple Sclerosis
- Early Onset of Efficacy After Erenumab Treatment in Chronic and Episodic Migraines